As blockbuster GLP-1 injectables like Mounjaro, Wegovy and Ozempic gain traction in India, doctors stress that careful ...

A conserved signaling axis linking Drosophila adipose tissue to nephrocyte function reveals how obesity can drive kidney dysfunction and points to new opportunities for therapeutic intervention.

Objectives Given the rapidly evolving therapeutic landscape for type 2 diabetes (T2D) and chronic kidney disease (CKD), this study aimed to characterise the clinical profiles and real-world outcomes ...

These popular weight-loss drugs are already known for treating diabetes and helping people lose weight. Could they also add years to your life?

Retatrutide treatment resulted in significant improvements in WOMAC pain scores and body weight compared with placebo in the TRIUMPH-4 trial.

SAN ANTONIO, Nov. 25, 2025 – From metabolic villain to hero? The hormone glucagon that raises blood sugar is now getting a second look to see how it actually contributes to insulin secretion, glucose ...

All right. Good morning, everyone, to Jefferies' London Healthcare Conference 2025. My name is Roger Song, one of the senior analyst covering SMID-cap biotech in the U.S. It is my great pleasure to ...

On Thursday, 20 November 2025, Altimmune (NASDAQ:ALT) presented at the Jefferies London Healthcare Conference 2025, providing a strategic overview of its development of pemvidutide, a glucagon GLP-1 ...

Erectile dysfunction (ED) is a common yet frequently underrecognized microvascular complication of diabetes, affecting up to three out of four individuals. Key contributing factors include advancing ...

Royalty-free licenses let you pay once to use copyrighted images and video clips in personal and commercial projects on an ongoing basis without requiring additional payments each time you use that ...

Purpose and Hypothesis: Despite the increasing number of donation after circulatory death (DCD) heart transplants over the last decade, there is no promising cardioprotective agent to improve DCD ...

NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO) shares are trading higher Thursday after the company announced the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) ...